These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 33992807)

  • 1. Single AAV-mediated CRISPR-Nme2Cas9 efficiently reduces mutant hTTR expression in a transgenic mouse model of transthyretin amyloidosis.
    Wen J; Cao T; Wu J; Chen Y; Zhi S; Huang Y; Zhen P; Wu G; Aagaard L; Zhong J; Liang P; Huang J
    Mol Ther; 2022 Jan; 30(1):164-174. PubMed ID: 33992807
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical development of an antisense therapy for the treatment of transthyretin-associated polyneuropathy.
    Ackermann EJ; Guo S; Booten S; Alvarado L; Benson M; Hughes S; Monia BP
    Amyloid; 2012 Jun; 19 Suppl 1():43-4. PubMed ID: 22494066
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sensory nerve degeneration in a mouse model mimicking early manifestations of familial amyloid polyneuropathy due to transthyretin Ala97Ser.
    Kan HW; Chiang H; Lin WM; Yu IS; Lin SW; Hsieh ST
    Neuropathol Appl Neurobiol; 2018 Dec; 44(7):673-686. PubMed ID: 29423915
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gene therapy approach to FAP: in vivo influence of T119M in TTR deposition in a transgenic V30M mouse model.
    Batista AR; Gianni D; Ventosa M; Coelho AV; Almeida MR; Sena-Esteves M; Saraiva MJ
    Gene Ther; 2014 Dec; 21(12):1041-50. PubMed ID: 25273354
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis.
    Gillmore JD; Gane E; Taubel J; Kao J; Fontana M; Maitland ML; Seitzer J; O'Connell D; Walsh KR; Wood K; Phillips J; Xu Y; Amaral A; Boyd AP; Cehelsky JE; McKee MD; Schiermeier A; Harari O; Murphy A; Kyratsous CA; Zambrowicz B; Soltys R; Gutstein DE; Leonard J; Sepp-Lorenzino L; Lebwohl D
    N Engl J Med; 2021 Aug; 385(6):493-502. PubMed ID: 34215024
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treating Transthyretin Amyloidosis via Adeno-Associated Virus Vector Delivery of Meganucleases.
    Greig JA; Breton C; Ashley SN; Martins KM; Gorsuch C; Chorazeczewski JK; Furmanak T; Smith MK; Zhu Y; Bell P; Shoop W; Li H; Smith J; Tomberlin G; Clark P; Mitchell TW; Buza EL; Yan H; Jantz D; Wilson JM
    Hum Gene Ther; 2022 Nov; 33(21-22):1174-1186. PubMed ID: 36375122
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liver-directed drugs for transthyretin-mediated amyloidosis.
    Brannagan TH; Berk JL; Gillmore JD; Maurer MS; Waddington-Cruz M; Fontana M; Masri A; Obici L; Brambatti M; Baker BF; Hannan LA; Buchele G; Viney NJ; Coelho T; Nativi-Nicolau J
    J Peripher Nerv Syst; 2022 Dec; 27(4):228-237. PubMed ID: 36345805
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical evaluation of RNAi as a treatment for transthyretin-mediated amyloidosis.
    Butler JS; Chan A; Costelha S; Fishman S; Willoughby JL; Borland TD; Milstein S; Foster DJ; Gonçalves P; Chen Q; Qin J; Bettencourt BR; Sah DW; Alvarez R; Rajeev KG; Manoharan M; Fitzgerald K; Meyers RE; Nochur SV; Saraiva MJ; Zimmermann TS
    Amyloid; 2016 Jun; 23(2):109-18. PubMed ID: 27033334
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatic production of transthyretin L12P leads to intracellular lysosomal aggregates in a new somatic transgenic mouse model.
    Batista AR; Sena-Esteves M; Saraiva MJ
    Biochim Biophys Acta; 2013 Aug; 1832(8):1183-93. PubMed ID: 23579071
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modeling familial amyloidotic polyneuropathy (Transthyretin V30M) in Drosophila melanogaster.
    Berg I; Thor S; Hammarström P
    Neurodegener Dis; 2009; 6(3):127-38. PubMed ID: 19372706
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence for early cytotoxic aggregates in transgenic mice for human transthyretin Leu55Pro.
    Sousa MM; Fernandes R; Palha JA; Taboada A; Vieira P; Saraiva MJ
    Am J Pathol; 2002 Nov; 161(5):1935-48. PubMed ID: 12414539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patisiran for the treatment of hereditary transthyretin-mediated amyloidosis.
    Yang J
    Expert Rev Clin Pharmacol; 2019 Feb; 12(2):95-99. PubMed ID: 30644768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Expression of Chemokines Is Downregulated in a Pre-Clinical Model of TTR V30M Amyloidosis.
    Moreira J; Costelha S; Saraiva M; Saraiva MJ
    Front Immunol; 2021; 12():650269. PubMed ID: 34093538
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cellular secretion and cytotoxicity of transthyretin mutant proteins underlie late-onset amyloidosis and neurodegeneration.
    Ibrahim RB; Yeh SY; Lin KP; Ricardo F; Yu TY; Chan CC; Tsai JW; Liu YT
    Cell Mol Life Sci; 2020 Apr; 77(7):1421-1434. PubMed ID: 31728576
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Gene therapy in familial amyloidotic polyneuropathy by single-stranded oligonucleotides (SSOs)].
    Nakamura M; Ando Y
    Rinsho Byori; 2004 Oct; 52(10):804-12. PubMed ID: 15624495
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficiency of silencing RNA for removal of transthyretin V30M in a TTR leptomeningeal animal model.
    Gonçalves P; Martins H; Costelha S; Maia LF; Saraiva MJ
    Amyloid; 2016 Dec; 23(4):249-253. PubMed ID: 27884058
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ligand conjugated antisense oligonucleotide for the treatment of transthyretin amyloidosis: preclinical and phase 1 data.
    Viney NJ; Guo S; Tai LJ; Baker BF; Aghajan M; Jung SW; Yu RZ; Booten S; Murray H; Machemer T; Burel S; Murray S; Buchele G; Tsimikas S; Schneider E; Geary RS; Benson MD; Monia BP
    ESC Heart Fail; 2021 Feb; 8(1):652-661. PubMed ID: 33283485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RNA-targeting and gene editing therapies for transthyretin amyloidosis.
    Aimo A; Castiglione V; Rapezzi C; Franzini M; Panichella G; Vergaro G; Gillmore J; Fontana M; Passino C; Emdin M
    Nat Rev Cardiol; 2022 Oct; 19(10):655-667. PubMed ID: 35322226
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amyloid deposition in a mouse model humanized at the transthyretin and retinol-binding protein 4 loci.
    Li X; Lyu Y; Shen J; Mu Y; Qiang L; Liu L; Araki K; Imbimbo BP; Yamamura KI; Jin S; Li Z
    Lab Invest; 2018 Apr; 98(4):512-524. PubMed ID: 29330472
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allele specific expression of the transthyretin gene in swedish patients with hereditary transthyretin amyloidosis (ATTR V30M) is similar between the two alleles.
    Norgren N; Hellman U; Ericzon BG; Olsson M; Suhr OB
    PLoS One; 2012; 7(11):e49981. PubMed ID: 23185504
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.